Of these, 631 patients received 2L Ram-Pac and 40 received 2L FOLFIRI-Ram. After matching, the final sample size was 240 patients who received Ram-Pac and 40 who received FOLFIRI-Ram. Baseline clinical and laboratory characteristics were well-balanced. The median OS from initiation of 2L ...
Ramucirumab was first approved to treat advanced or metastatic gastric orgastroesophageal junction(GEJ) cancer whose disease had progressed during or after prior treatment with fluoropyrimidine- or platinum-containing chemotherapy[39, 40], which was on the basis of a multinational randomized double-blind...
Bevacizumab (BV) or Ramucirumab (RAM) combining with FOLFIRI (infusional 5-fluorouracil, leucovorin and irinotecan) improves progression-free survival (PFS) and overall survival (OS) in second-line chemotherapy for patients with metastatic colorectal cancer (mCRC). However, no direct comparison has ...
Ramucirumab is a VEGFR-2 antibody that has proven to prolong overall survival (OS) in patients with pretreated metastatic gastric/gastrooesophageal junction (GEJ) adenocarcinoma. We present data from patients treated with ramucirumab and paclitaxel or FOLFIRI after failure of at least one platinum- an...
Tabernero J, Yoshino T, Cohn AL et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin...
ramucirumab (RAM) -based therapy in patients with advanced colorectal cancer: Efficacy comparison using real-world data evidence from... 71#Background:FOLFIRI in combination with Aflibercept (AFL) or Ramucirumab (RAM) prolongs overall survival compared with FOLFIRI alone in patients with adv... ...
2015 年 4 月 24 日/美通社/——礼来公司(纽约证券交易所代码:LLY)已获得美国食品药品监督管理局(FDA)第四次批准Cyramza(雷莫西尤单抗)。Cyramza(雷莫西尤单抗注射液 10 mg/mL 溶液)现在也适用于与 FOLFIRI(伊立替康、亚叶酸和 5-氟尿嘧啶)化疗联合用于治疗既往治疗期间或之后疾病进展的转移性结直肠癌(mCRC)...
Ramucirumab With FOLFIRI in Metastatic Colorectal CancerMatthew Stenger
Introduction: The aim of this study was to provide a review of the clinical evidence for use of ramucirumab (RAM) plus folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan (FOLFIRI) or irinotecan as second-line treatment in gastroesophageal adenocarcinoma (GEA). Method...
Ramucirumab Added to FOLFIRI Yields Results Similar to Bevacizumab or Aflibercept in Second‑Line Colorectal CancerCaroline Helwick